SLC5A2 and Hyperglycemia: Empagliflozin (Jardiance®; Boehringer Ingelheim), a highly selective SGLT2 inhibitor [1], is approved in Europe, Japan, and the US for the treatment of hyperglycemia in patients with T2D [4, 5].